Juvenile Rheumatoid Arthritis

Amgen86 enrolled

Overview

The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Juvenile Chronic Arthritis

Interventions

AnakinraDRUG

anakinra

PlaceboDRUG

placebo

Eligibility

Sex: ALLMin age: 2 YearsMax age: 17 Years

Medical Language ↔ Plain English

* Male or female age 2-17 yrs inclusive \* Minimum weight 10 KG \* Diagnosis of Chronic Arthritis

Outcomes

Primary Outcomes

The primary outcome of the study was to evaluate the safety of anakinra

Time frame: 28 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.